Sebastian Gensior

Introduction The Variable Capital Company (VCC) represents a transformative development in Singapore's fund management landscape, particularly for healthcare and life sciences investments. Introduced under the Variable Capital Companies Act 2018 and effective from January 14, 2020, the VCC provides a sophisticated corporate structure designed to enhance Singapore'

Introduction Special Purpose Vehicles (SPVs) play a pivotal role in the pharmaceutical and biotechnology sectors, facilitating innovative financing and structuring strategies. An SPV is a separate legal entity created for a specific purpose, with its own assets and liabilities, distinct from the sponsoring company [source]. By isolating assets or business

Bankruptcy remoteness is a crucial concept in structuring financial deals — especially royalty financing transactions in the biotechnology and pharmaceutical industry. In simple terms, bankruptcy remoteness means arranging a deal so that if one party (typically the biotech company or originator) goes bankrupt, the assets or cash flows involved in the

The week saw concentrated M&A activity focused on MASH and neurological assets totalling over $10 billion in deal value, alongside $665M in Series A venture rounds. No royalty financing deals announced during this specific week, though substantial partnership and manufacturing agreements supplemented major acquisitions. Acquisitions and M&

The Allure of the "Up To" Deal Every so often, a biotech startup announces a blockbuster partnership with a big pharmaceutical company, and champagne corks start popping. The press release trumpets a headline number: "Small Biotech X signs deal worth up to $500 million!" Founders daydream

Executive Summary CureDuchenne Ventures does not operate as a traditional venture capital firm. Instead, it represents a venture philanthropy model where a nonprofit organization makes equity investments in biotechnology companies using donor dollars, targeting a single rare disease: Duchenne muscular dystrophy. This organizational structure creates unique dynamics, incentives, and constraints

Introduction Rome Therapeutics is a Boston-based biotechnology company on a mission to drug the "dark genome" – the vast portion of human DNA once dismissed as "junk" but now known to harbor repetitive elements implicated in disease. Founded in 2020 by CEO Rosana Kapeller, M.D., Ph.

Introduction In recent months, several major biopharma companies have dramatically scaled back or outright halted their gene and cell therapy programs. This trend—highlighted by Biogen's decision to discontinue all adeno-associated virus (AAV) gene therapy research and Takeda's move to exit the cell therapy field—has

Introduction Bristol Myers Squibb (BMS) and Takeda have recently joined forces with several peers in an ambitious data-sharing venture to advance artificial intelligence (AI) in drug discovery according to Reuters. Alongside AbbVie, Johnson & Johnson (J&J), and Astex Pharmaceuticals, they will pool proprietary research data -- specifically, thousands

Executive Overview Pharmaceutical royalties occupy a complex regulatory landscape where classification depends fundamentally on structure rather than asset type. As of October 2025, no jurisdiction treats pharmaceutical royalties as a distinct regulated asset class. Instead, regulatory treatment hinges on whether royalties are packaged as direct bilateral contracts (typically outside securities